<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941031</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2211</org_study_id>
    <secondary_id>2008-007525-39</secondary_id>
    <nct_id>NCT00941031</nct_id>
  </id_info>
  <brief_title>AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether, in patients with moderate to severe
      plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis
      symptoms and the extent to which the patient's body area is affected by the disease (compared
      to placebo).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75 Achievement After 12 Weeks of Treatment, Compared to Placebo.</measure>
    <time_frame>13 weeks</time_frame>
    <description>Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Efficacy of Two Maintenance Regimens of AIN457 With Respect to PASI 75 Achievement at Least Once From Week 21 to 29</measure>
    <time_frame>week 21 to 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously With Respect Participants Who Reported Either an IGA 0 or 1 After 12 Weeks of Treatment, Compared to Placebo</measure>
    <time_frame>13 weeks</time_frame>
    <description>The investigator's global assessment (IGA) was used to evaluate overall psoriatic disease, with scores ranging from 0 (clear) to 5 (very severe disease). Treatment success was defined as patients who achieved IGA 0 or 1 and improvement of at least 2 points on the IGA scale compared to baseline. The IGA rating score for involvement of hands and feet ranged from 0 (clear) to 4 (severe).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">404</enrollment>
  <condition>Chronic Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>Induction Single Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction with single injection - &quot;Single&quot;: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Monthly Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction with monthly injections - &quot;Monthly&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Induction Early Loading Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early loading induction - &quot;Early&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457</intervention_name>
    <arm_group_label>Induction Single Dose</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457A</intervention_name>
    <description>Induction with monthly injections - &quot;Monthly&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9</description>
    <arm_group_label>Induction Monthly Dose</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AIN457A</intervention_name>
    <description>Early loading induction - &quot;Early&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5</description>
    <arm_group_label>Induction Early Loading Dose</arm_group_label>
    <other_name>Secukinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - &quot;Placebo&quot;: Placebo administered at weeks 1, 2, 3, 5, 9</description>
    <arm_group_label>Placebo Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women at least 18 years of age at time of consent

          -  Chronic plaque-type psoriasis diagnosed for at least 6 months at time of randomization

          -  At time of randomization, moderate to severe psoriasis as defined by:

               -  PASI score of 12 or greater and

               -  IGA score of 3 or greater and

               -  Body Surface Area (BSA) affected by plaque-type psoriasis of 10 % or greater

          -  At screening and randomization, chronic plaque-type psoriasis considered inadequately
             controlled by:

               -  topical treatment and/or

               -  phototherapy and/or

               -  previous systemic therapy

        Exclusion Criteria:

          -  Patients meeting any of the following criteria will be excluded from entry into the
             study:

          -  Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and
             guttate psoriasis) at screening or randomization

          -  Drug-induced psoriasis (i.e. new onset or current exacerbation from beta-blockers,
             calcium channel inhibitors or lithium) and randomization

          -  Ongoing use of prohibited psoriasis treatments (e.g., topical or systemic
             corticosteroids, UV therapy) at randomization. Washout periods detailed in the study
             protocol have to be adhered to

          -  Ongoing use of other prohibited treatments at randomization. Washout periods detailed
             in the study protocol have to be adhered to. All prior concomitant medications must be
             on a stable dose for at least four weeks before study drug administration

          -  Known immunosuppression (e.g., AIDS) at screening and / or randomization

          -  History or evidence of active tuberculosis at screening. All patients will be tested
             for tuberculosis status using a blood test (QuantiFERON®-TB Gold In-Tube). Patients
             with evidence of latent tuberculosis may enter the trial after sufficient treatment
             has been initiated according to local regulations.

          -  Active systemic infections (other than common cold) during the two weeks before
             randomization (e.g., hepatitis)

          -  At screening, history or symptoms of malignancy of any organ system (other than
             history of basal cell carcinoma and / or up to three squamous cell carcinomas of the
             skin, if successful treatment has been performed, with no signs of recurrence; actinic
             keratoses, if present at screening, should be treated according to standard therapy
             before randomization), treated or untreated, within the past 5 years, regardless of
             whether there is evidence of local recurrence or metastases

          -  History of congestive heart failure (NYHA functional classification ≥III) at screening
             and / or randomization

          -  History of severe hypersensitivity to any human or humanized biological agents
             (antibody or soluble receptor) at screening and / or randomization

          -  Any severe, progressive or uncontrolled medical condition at randomization that in the
             judgment of the investigator prevents the patient from participating in the study

          -  Pregnant or nursing (lactating) women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clinton Twp.</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>066-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergen</city>
        <zip>NO-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ålesund</city>
        <zip>6017</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2009</study_first_submitted>
  <study_first_submitted_qc>July 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2009</study_first_posted>
  <results_first_submitted>January 30, 2015</results_first_submitted>
  <results_first_submitted_qc>March 23, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2015</results_first_posted>
  <disposition_first_submitted>May 31, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 31, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 6, 2012</disposition_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe chronic plaque-type psoriasis</keyword>
  <keyword>AIN457</keyword>
  <keyword>dermatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Induction Single Dose</title>
          <description>Induction with single injection - &quot;Single&quot;: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12</description>
        </group>
        <group group_id="P2">
          <title>Induction Monthly Dose</title>
          <description>Induction with monthly injections - &quot;Monthly&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12</description>
        </group>
        <group group_id="P3">
          <title>Induction Early Loading</title>
          <description>Early loading induction - &quot;Early&quot;: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12</description>
        </group>
        <group group_id="P4">
          <title>Placebo Dose</title>
          <description>Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12</description>
        </group>
        <group group_id="P5">
          <title>Fixed Interval</title>
          <description>Fixed-time interval regimen - &quot;FI&quot;: secukinumab (AIN457) 150 mg s.c. administered at Week 13 and at Week 25 and placebo at regular scheduled visit at which a start of relapse was observed, Week 21 to Week 29</description>
        </group>
        <group group_id="P6">
          <title>Start of Relapse</title>
          <description>Treatment at start of relapse regimen - &quot;SR&quot;: Placebo administered at Week 13 and possibly at Week 25 if no start of relapse observed, and secukinumab (AIN457) 150 mg s.c. administered at regular scheduled visit at which a start of relapse was observed, Week 21 to Week 29</description>
        </group>
        <group group_id="P7">
          <title>Open Label</title>
          <description>Non responders and partial responders at Week 13 and patients who experienced 2 consecutive relapses at scheduled visits from Week 13 onwards were eligible to enter the Open Label phase - &quot;OL&quot;: secukinumab (AIN457) 150 mg s.c. administered every 4 weeks.21 to Week 29</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="127"/>
                <participants group_id="P4" count="58"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adminstative Problems</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P2" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P3" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P4" count="0">Non Responders treated with an open label regimen.</participants>
                <participants group_id="P5" count="65">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P6" count="67">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P7" count="247">Non Responders treated with an open label regimen.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P2" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P3" count="0">Responders at week 13 were re randomized to one of the maintenance treatment arms in a ratio of 1:1</participants>
                <participants group_id="P4" count="0">Non Responders treated with an open label regimen.</participants>
                <participants group_id="P5" count="56"/>
                <participants group_id="P6" count="61"/>
                <participants group_id="P7" count="204"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="43"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Problems</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Induction Single Dose</title>
          <description>Baseline through Week 12</description>
        </group>
        <group group_id="B2">
          <title>Induction Monthly Dose</title>
        </group>
        <group group_id="B3">
          <title>Induction Early Loading Dose</title>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="133"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="404"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="11.32"/>
                    <measurement group_id="B2" value="44.2" spread="12.96"/>
                    <measurement group_id="B3" value="44.5" spread="12.45"/>
                    <measurement group_id="B4" value="44.2" spread="12.59"/>
                    <measurement group_id="B5" value="44.1" spread="12.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B5" value="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75 Achievement After 12 Weeks of Treatment, Compared to Placebo.</title>
        <description>Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment</description>
        <time_frame>13 weeks</time_frame>
        <population>(Full analysis set, LOCF) Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Single Dose</title>
            <description>Induction with single injection – “Single”: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12</description>
          </group>
          <group group_id="O2">
            <title>Induction Monthly Dose</title>
            <description>Induction with monthly injections – “Monthly”: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12</description>
          </group>
          <group group_id="O3">
            <title>Induction Early Loading Dose</title>
            <description>Early loading induction – “Early”: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12</description>
          </group>
          <group group_id="O4">
            <title>Placebo Dose</title>
            <description>Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque-type Psoriasis With Respect to PASI 75 Achievement After 12 Weeks of Treatment, Compared to Placebo.</title>
          <description>Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment</description>
          <population>(Full analysis set, LOCF) Number (%) of patients achieving PASI 50, PASI 75, PASI 90, by visit and induction treatment</population>
          <units>Participants achieving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="101"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Efficacy of Two Maintenance Regimens of AIN457 With Respect to PASI 75 Achievement at Least Once From Week 21 to 29</title>
        <time_frame>week 21 to 29</time_frame>
        <population>(Full analysis set, LOCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Maintenance Fixed Interval</title>
            <description>Fixed-time interval regimen – “FI”: secukinumab (AIN457) 150 mg s.c. administered at Week 13 and at Week 25 and placebo at regular scheduled visit at which a start of relapse was observed, Week 21 to Week 29</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Start of Relapse</title>
            <description>Treatment at start of relapse regimen – “SR”: Placebo administered at Week 13 and possibly at Week 25 if no start of relapse observed, and secukinumab (AIN457) 150 mg s.c. administered at regular scheduled visit at which a start of relapse was observed, Week 21 to Week 29</description>
          </group>
          <group group_id="O3">
            <title>Maintenance Open Label</title>
            <description>Non responders and partial responders at Week 13 and patients who experienced 2 consecutive relapses at scheduled visits from Week 13 onwards were eligible to enter the Open Label phase – “OL”: secukinumab (AIN457) 150 mg s.c. administered every 4 weeks.21 to Week 29</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy of Two Maintenance Regimens of AIN457 With Respect to PASI 75 Achievement at Least Once From Week 21 to 29</title>
          <population>(Full analysis set, LOCF)</population>
          <units>Participants achieving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously With Respect Participants Who Reported Either an IGA 0 or 1 After 12 Weeks of Treatment, Compared to Placebo</title>
        <description>The investigator’s global assessment (IGA) was used to evaluate overall psoriatic disease, with scores ranging from 0 (clear) to 5 (very severe disease). Treatment success was defined as patients who achieved IGA 0 or 1 and improvement of at least 2 points on the IGA scale compared to baseline. The IGA rating score for involvement of hands and feet ranged from 0 (clear) to 4 (severe).</description>
        <time_frame>13 weeks</time_frame>
        <population>Full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Induction Single Dose</title>
            <description>Induction with single injection – “Single”: secukinumab (AIN457) 150 mg s.c. administered at Week 1, Baseline through Week 12</description>
          </group>
          <group group_id="O2">
            <title>Induction Monthly Dose</title>
            <description>Induction with monthly injections – “Monthly”: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9, Baseline through Week 12</description>
          </group>
          <group group_id="O3">
            <title>Induction Early Loading Dose</title>
            <description>Early loading induction – “Early”: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5, Baseline through Week 12</description>
          </group>
          <group group_id="O4">
            <title>Placebo Dose</title>
            <description>Placebo administered at weeks 1, 2, 3, 5, 9, Baseline through Week 12</description>
          </group>
        </group_list>
        <measure>
          <title>The Efficacy of Three Induction Regimens of AIN457 Administered Subcutaneously With Respect Participants Who Reported Either an IGA 0 or 1 After 12 Weeks of Treatment, Compared to Placebo</title>
          <description>The investigator’s global assessment (IGA) was used to evaluate overall psoriatic disease, with scores ranging from 0 (clear) to 5 (very severe disease). Treatment success was defined as patients who achieved IGA 0 or 1 and improvement of at least 2 points on the IGA scale compared to baseline. The IGA rating score for involvement of hands and feet ranged from 0 (clear) to 4 (severe).</description>
          <population>Full analysis set</population>
          <units>Participants achieving goal</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="137"/>
                <count group_id="O3" value="132"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0=clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1= almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2= mild disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3= moderate disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4=severe disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5= very serious disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>INDUCTION: Single</title>
          <description>INDUCTION: Early loading induction - 'Early'</description>
        </group>
        <group group_id="E2">
          <title>INDUCTION: Monthly</title>
          <description>INDUCTION: with monthly injections - 'Monthly'</description>
        </group>
        <group group_id="E3">
          <title>INDUCTION: Early</title>
          <description>INDUCTION: with single injection - 'Single'</description>
        </group>
        <group group_id="E4">
          <title>INDUCTION: Placebo</title>
          <description>INDUCTION: Placebo - 'Placebo'</description>
        </group>
        <group group_id="E5">
          <title>MAINTENANCE: Fixed Interval</title>
          <description>MAINTENANCE: Fixed-time interval regimen - 'FI'</description>
        </group>
        <group group_id="E6">
          <title>MAINTENANCE: Start of Relapse</title>
          <description>MAINTENANCE: Treatment at start of relapse regimen - 'SR'</description>
        </group>
        <group group_id="E7">
          <title>MAINTENANCE: Open Label</title>
          <description>MAINTENANCE: Open label Non responders and partial responders at Week 13 and patients who experienced 2 consecutive relapses at scheduled visits from Week 13 onwards were eligible to enter the Open Label phase – “OL”: secukinumab (AIN457) 150 mg s.c. administered every 4 weeks.</description>
        </group>
        <group group_id="E8">
          <title>FOLLOW-UP: Fixed Interval</title>
          <description>FOLLOW-UP: Fixed-time interval regimen - 'FI'</description>
        </group>
        <group group_id="E9">
          <title>FOLLOW-UP: Start of Relapse</title>
          <description>FOLLOW-UP: Treatment at start of relapse regimen - 'SR'</description>
        </group>
        <group group_id="E10">
          <title>FOLLOW-UP: Open Label</title>
          <description>FOLLOW-UP: Open label</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Colonic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Testis cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythrodermic psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="83" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="65"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="72"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

